Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GNE-207 is a selective and orally bioavailable inhibitor of the bromodomain of CBP (IC50: 1 nM). It has a selective index of <2500-fold against BRD4 (1). GNE-207 displays excellent CBP potency (EC50: 18 nM for MYC expression in MV-4-11 cells).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 2,120.00 | |
50 mg | 8-10 weeks | $ 2,780.00 | |
100 mg | 8-10 weeks | $ 3,700.00 |
Description | GNE-207 is a selective and orally bioavailable inhibitor of the bromodomain of CBP (IC50: 1 nM). It has a selective index of >2500-fold against BRD4 (1). GNE-207 displays excellent CBP potency (EC50: 18 nM for MYC expression in MV-4-11 cells). |
Targets&IC50 | BRD41:3.1 μM, CBP:1 nM |
In vivo | GNE-207 (5?mg/kg) displays moderate clearance in PK. It has an acceptable oral bioavailability. |
Molecular Weight | 510.59 |
Formula | C29H30N6O3 |
CAS No. | 2158266-58-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 200 mg/mL (391.70 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GNE-207 2158266-58-9 Chromatin/Epigenetic Epigenetic Reader Domain GNE207 GNE 207 inhibitor inhibit